Publication:

Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301 (2011)

Author(s): Thomas HD, Wang LZ, Roche C, Bentley J, Cheng YZ, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, Newell DR

      • Date: 12-05-2011
      • Journal: European Journal of Cancer
      • Volume: 47
      • Issue: 13
      • Pages: 2052-2059
      • Publisher: Pergamon
      • Publication type: Article
      • Bibliographic status: Published

      Keywords: CDK2 Cell cycle Growth inhibition Pharmacokinetics Pharmacodynamics CELL-CYCLE CANCER-CELLS CDK2 ACTIVITY MYC CYCLIN-DEPENDENT-KINASE-2 PHOSPHORYLATION PROGRESSION THERAPY TARGETS

      Staff

      Professor Bernard Golding
      Senior Research Investigator